Anticonvulsants Market To 2016

Anticonvulsants Market To 2016
Various anticonvulsants, both branded and off-label are being used for the treatment of many indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder and anxiety. The patents of leading anticonvulsants such as Topamax (topiramate), Trileptal (oxcarbazepine), Depakote (divalproex sodium), Keppra (levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for management of the various indications has caused the emergence of generics for these anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market in the future.

For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Anti-convulsants-Market-to-2016-Cost-Advantage-and-Dosage-Convenience-Provided-by-Generic-Anticonvulsants-Will-Limit-Commercial-Opportunities-for-Novel-Therapies&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of the total anticonvulsants product pipeline is in Phase III clincal studies. The majority of these molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant market.

Lyrica (pregabalin) is the branded anriconvulsant product of Pfizer.Lyrica is indicated for the treatment of the epilepsy, fibromyalgia and neuropathic pain. Lyrica along with Neurontin (gabapentin) is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $ 2.57 billion and $ 2.84 billion for Pfizer, in 2008 and 2009 respectively.

GBI Research, the leading business intelligence provider, has released its latest research, Anticonvulsants Market to 2016 – Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies, which provides insights into global anticonvulsant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline.

For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Anti-convulsants-Market-to-2016-Cost-Advantage-and-Dosage-Convenience-Provided-by-Generic-Anticonvulsants-Will-Limit-Commercial-Opportunities-for-Novel-Therapies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate – a comprehensive resource for business information needs.

Find More Gold 2016 Articles

Leave a Reply